Why is Stereotaxis stock sliding today?

Stereotaxis (STXS) fell 14.6% after Q3 2026 results missed estimates, with a $0.07 adjusted loss per share and $8.9M revenue. Supply shortages of MAGiC catheters and a $24M convertible note financing at $1.21/share raised concerns. TD Cowen cut its price target to $2.00. The stock hit a 52-week low of $0.80.

Original reporting
Published Nov 11, 2026, 4:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 4:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$STXS
Bearish
high confidence
Mentioned
$STXS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$STXSBearishHigh
01

Why it matters

The earnings miss and dilutive financing triggered a sharp intraday sell‑off, highlighting near‑term profitability concerns.

02

Market read

STXS's stock fell 14.6% on earnings miss and financing news, contrasting with broader market gains.

03

What to watch

Potential upside from future catheter supply improvements and cash‑flow from the convertible note.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

STXS reported a Q3 loss of $0.07 per share versus a $0.05 expected loss, with revenue $8.9M versus $9.9M forecast.

Company-level read

Ticker impact

$STXSBearishHigh confidence
Context

Q3 2026 earnings miss and dilutive convertible note financing drove a 14.6% drop to $0.80.

Expected impact

downward pressure as investors price in missed estimates and dilution.

Evidence & confidence

Both revenue and EPS missed expectations; convertible note adds dilution risk.

Market effects

Medical robotics sector may see relative outperformance as STXS underperforms.

U.S. small‑cap biotech/medical device segment faces heightened volatility.

Limited; impact confined to U.S. equity markets.

Counterpoint

The price dip may present a short‑term buying opportunity if the backlog resolves.

Key entities

  • Stereotaxis

    Medical robotics firm reporting Q3 results.

  • Osypka

    Supplier of MAGiC catheters experiencing shipment shortfall.

Related articles

$STXSMedAI 8/10

20 robotic heart procedures had no device-related adverse events.

Stereotaxis (NYSE: STXS) announced 100% clinical success and no device-related adverse events in 20 first-in-human robotic heart procedures using Robocath's next-generation system. The study, presented at TCT 2026, showed 95% technical success and no physician radiation exposure. Robocath is a subsidiary of Stereotaxis, focusing on advanced robotic innovations for interventional cardiology.

$STXSMedAI 8/10

Stereotaxis (STXS) Q2 2026 Earnings Call Transcript

Stereotaxis (STXS) reported Q2 2026 revenue of $7.7M, down from $8.8M YoY due to no robotic system delivery. Robotic catheter revenue grew 270% sequentially to $1M. Recurring revenue increased to $6.2M. Gross margin was 58%. The company expects cash flow profitability by H1 2027 and guided Q3/Q4 recurring revenue at $7M and $8M, respectively. Management highlighted supply constraints and transition risks.

$STXSMed

Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates

Stereotaxis, Inc. (STXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ● Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially ● First GenesisX robotic system purchase by US hospital to be installed this fall ● Multiple Synchrony digi

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.